Analysis of real-world data compared patients on GIMOTI (n=51) to Oral Metoclopramide (n=41), both taking GLP-1s, showing ...

Nov. 07, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on ...

Metoclopramide use during early pregnancy was not associated with excess risk for congenital malformations. In the U.S., treatment of nausea and vomiting during early pregnancy usually involves ...

Metoclopramide is used for the symptomatic treatment of post-operative or chemotherapy-induced nausea and vomiting, gastroesophageal reflux disease and gastroparesis. Metoclopramide is generally ...

Evoke Pharma Inc (NASDAQ:EVOK) shares are trading higher Monday after the company presented GLP-1 data for users with ...

Evoke Pharma (EVOK) shares rocketed 90% on positive data for its nasal drug Gimoti in the treatment of stomach paralysis in ...

Metoclopramide is a central dopamine D2-receptor antagonist used as an antiemetic and gastroprokinetic agent in dogs and cats 1,2,3,4. It has been used experimentally in pigeons as an antiemetic ...

Approved to treat diabetic gastroparesis, Gimoti is co-marketed with Eversana. Evoke underlined that nasal delivery provides ...

Report on how AI is redefining market landscape - The global gastroparesis drugs market  size is estimated to grow by USD 1.42 billion from 2024-2028, according to Technavio. The market is estimated ...

Evoke Pharma Inc (NASDAQ: EVOK) opened well over 100% up on Monday after reporting positive results for a study on its ...

The company developed, commercialized and markets GIMOTI, a nasal spray formulation of metoclopramide, for the relief of ...

Evoke Pharma shares rose 70% on Monday after presenting data on Gimoti in GLP-1 users. Shares were trading around $9 in recent trading. The stock is down more than 28% on the year so far.